Study guide
Staging, Grading, Prognosis, and Performance Status
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Staging, Grading, Prognosis, and Performance Status
Key Takeaways Explain This Topic AI
Stage describes anatomic extent or disease-specific risk grouping; grade describes how abnormal or aggressive tumor cells appear.
TNM uses tumor size or invasion (T), nodes (N), and metastasis (M); hematologic and some solid tumors use other systems.
Prognosis depends on stage, grade, biomarkers, performance status, comorbidities, organ function, treatment response, and patient goals.
ECOG performance status runs 0 (fully active) to 5 (dead) and shapes treatment tolerance, trial eligibility, and escalation needs.
Nurses coordinate staging workups, document functional change in precise language, and report rapid decline without assigning stage.
Last updated: June 2026
- Staging, Grading, Prognosis, and Performance Status
- Separate the Four Concepts
Patients ask "What stage am I?" and "How bad is it?" The OCN must keep four ideas distinct. Stage is the extent of disease. Grade is how abnormal the cells look or how aggressively they behave. Prognosis is the likely course based on many factors. Performance status is how the patient functions daily. Nurses reinforce provider explanations, assess change, and coordinate completion of staging.
- Concept Meaning Nursing application
- Stage Extent of disease Anticipate treatment sequence, urgency, education
- Grade Cell differentiation / aggressiveness Reinforce pathology without overinterpreting
- Prognosis Expected course Redirect survival estimates to the team; assess support needs
- Performance status Functional reserve Assess tolerance, safety, referral needs
- Staging Basics: TNM and Beyond
For most solid tumors, the American Joint Committee on Cancer (AJCC) TNM system is the foundation. T describes primary tumor size or local invasion (T1-T4). N describes regional lymph nodes (N0-N3). M describes distant metastasis (M0 or M1). These combine into stage groups, generally I through IV, with rules that differ by cancer type.
Clinical stage (c) uses pre-treatment exam, imaging, biopsy, and endoscopy; pathologic stage (p) adds surgical findings. Restaging may follow neoadjuvant therapy or recurrence.
Many cancers use other systems: lymphomas use Ann Arbor / Lugano (stages I-IV with A/B for symptoms); leukemias are classified by lineage, genetics, and blast count rather than TNM; multiple myeloma uses the Revised International Staging System (beta-2 microglobulin, albumin, LDH, cytogenetics); gynecologic cancers use FIGO ; and central nervous system tumors rely on histology, World Health Organization (WHO) grade, molecular markers, and location. The key teaching point: "stage IV" does not mean the same prognosis or treatment across all cancers.
Grading and Classification
Grade reflects differentiation. Low-grade (well-differentiated) tumors resemble normal tissue and often grow slowly; high-grade (poorly differentiated) tumors look abnormal and behave aggressively. Disease-specific grading systems the OCN should recognize:
Prostate: Gleason score and Grade Group (1-5).
Breast: Nottingham (Scarff-Bloom-Richardson) grade 1-3.
Central nervous system: WHO grade 1-4 (glioblastoma is grade 4).
Soft-tissue sarcoma: FNCLCC grade based on differentiation, mitoses, and necrosis.
Classification names what the cancer is — adenocarcinoma, squamous cell carcinoma, diffuse large B-cell lymphoma, acute myeloid leukemia, melanoma, glioblastoma, osteosarcoma, seminoma. Accurate classification drives treatment pathway, expected spread pattern, and nursing education.
Prognosis Is Multifactorial
Stage alone does not set prognosis. Contributing factors include grade, histology, biomarkers, tumor burden, pace of disease, treatment response, resectability, performance status, age, comorbidities, nutrition, organ function, social support, and patient preferences. The OCN does not give survival estimates outside team guidance; instead the nurse explores understanding, documents questions, supports goals-of-care conversations, and connects patients with palliative care, social work, nutrition, rehabilitation, and psychosocial services.
Performance Status: A Daily-Use Tool
ECOG performance status runs 0 to 5:
- ECOG Description
- 0 Fully active, no restriction
- 1 Restricted in strenuous activity; ambulatory, light work
- 2 Ambulatory, self-care intact, no work; up more than 50% of waking hours
- 3 Limited self-care; in bed or chair more than 50% of waking hours
- 4 Completely disabled; no self-care; totally confined
- 5 Dead
The Karnofsky Performance Status (KPS) runs 0-100 in 10-point steps and conveys similar information. Performance status affects treatment tolerance, dose intensity, trial eligibility (many trials require ECOG 0-2), fall risk, home support, and urgency of evaluation.
Nurses often detect decline first. Ask what changed: walking distance, self-care, time in bed, oral intake, falls, dyspnea, pain, cognition, and caregiver workload. A rapid drop may signal progression, infection, metabolic emergency, cord compression, brain metastasis, thromboembolism, dehydration, anemia, or depression.
In Situ Versus Invasive and Why It Changes Everything
A distinction the OCN must master is carcinoma in situ (stage 0) versus invasive disease . In situ disease (for example, ductal carcinoma in situ of the breast) has not crossed the basement membrane, so it cannot metastasize and is often curable with local therapy. Once a tumor invades through the basement membrane, it gains access to lymphatics and blood vessels and can spread, which is why the same organ's cancer can range from highly curable to advanced. The nurse uses this to frame patient teaching realistically without overpromising, and to explain why the workup emphasizes whether and how far disease has spread.
Nursing Role and Communication
Nursing actions include coordinating staging scans, confirming pathology and biomarker reports are available, documenting a functional baseline, teaching why tests are needed, and escalating significant change.
Use exact language: "Previously walked two blocks; now cannot reach the bathroom without assistance" is far more useful than "weaker." Document performance status with a number when trained (ECOG or Karnofsky) plus the concrete behavior that supports it, because a falling performance status is one of the earliest objective signals of progression, toxicity, or a developing oncologic emergency, and it directly affects whether the patient still qualifies for aggressive treatment or a clinical trial.